natgillin/translations-raw huggingface dataset:
Neuropathic pain, prophylactic treatment of chronic tension type headache and prophylactic treatment of migraine prophylaxis 
Neuropatska bol, profilaktičko liječenje kronične tenzijske glavobolje i profilaktičko liječenje migrene
Uncommon Collapse conditions, worsening of cardiac failure. 
• stanje kolapsa • pogoršanje zatajenja srca
• the prophylactic treatment of chronic tension type headache (CTTH) in adults 
• profilaktičko liječenje kronične tenzijske glavobolje u odraslih
• have slow heart rate, 
• imate usporene otkucaje srca
Pharmacotherapeutic group 
Farmakoterapijska skupina
Annex III SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET 
Sažetak opisa svojstava lijeka, označivanje i uputa o lijeku
In contrast to the tablet serum curves which show a distinct initial peak, the capsule curves rise slowly to a plateau level with lower concentrations than the peak of the tablet curves. 
Za razliku od krivulja koje se odnose na vrijednosti u serumu nakon primjene tablete koje pokazuju izrazitu početnu vršnu vrijednost, krivulje nakon primjene kapsule polako rastu do platoa koji je na nižoj razini koncentracije nego što je vršna vrijednost krivulje nakon primjene tablete. tmax = 7,1 ± 1,9 sati; raspon 2,0 - 10,0 sati.
An ECG should be performed prior to initiating therapy with amitriptyline to exclude long QT syndrome. 
Noćna enureza Prije početka terapije amitriptilinom potrebno je napraviti EKG kako bi se isključio sindrom dugog
<[Saroten and associated names 75 mg, modified release tablets] Amitriptyline hydrochloride> 
<[Saroten i pridruženi imena 75 mg, tablete s prilagođenim oslobađanjem] amitriptilinklorid>
Reduced renal function This medicinal product can be given in usual doses to patients with renal failure. 
Ovaj se lijek može davati bolesnicima sa zatajenjem bubrega u uobičajenim dozama.
Treatment of the following will be decided on a case by case basis: - Wide QRS-intervals, cardiac failure and ventricular arrhythmias - Circulatory failure - Hypotension - Hyperthermia - Convulsions - Metabolic acidosis. 
- široki QRS interval, zatajenje srca i ventrikularne aritmije - zatajenje cirkulacije - hipotenzija - hipertermija - konvulzije
Rare side effect, may affect up to 1 in 1,000 people. 
Rijetka nuspojava, može se javiti u do 1 na 1000 osoba.
The recommended initial dose is 10 mg - 25 mg daily. 
Preporučena početna doza je 10 mg - 25 mg na dan.
CNS depressants: Amitriptyline may enhance the sedative effects of alcohol, barbiturates and other CNS depressants. 
Depresori središnjeg živčanog sustava (SŽS-a): Amitriptilin može pojačati sedativne učinke alkohola,
• dilated pupils 
• zapletaj crijeva
Antidepressants - Non-selective monoamine reuptake inhibitor (tricyclic antidepressant) ATC code: N 06 AA 09 
Antidepresivi - neselektivni inhibitor ponovne pohrane monoamina (triciklički antidepresiv)
• decreased heart rate 
• usporeni otkucaji srca
A starting dose of 10 mg - 25 mg in the evening is recommended. 
Preporučuje se početna doza od 10 mg - 25 mg navečer.
• Chronic tension type headache prophylaxis in adults 
• profilaksu kronične tenzijske glavobolje u odraslih
Sympathomimetic agents: Amitriptyline may potentiate the cardiovascular effects of adrenaline, ephedrine, isoprenaline, noradrenaline, phenylephrine, and phenylpropanolamine (e.g. as contained in local and general anaesthetics and nasal decongestants). 
izoprenalina, noradrenalina, fenilefrina i fenilpropanolamina (npr. kakve sadrže anestetici za lokalnu i opću anesteziju i nosni dekongestivi).
NAME OF THE MEDICINAL PRODUCT Saroten and associated names 25 mg prolonged-release capsules, hard Saroten and associated names 50 mg prolonged-release capsules, hard Saroten and associated names 75 mg, modified release tablets 
Saroten i pridružena imena 25 mg kapsule s produljenim oslobađanjem, tvrde Saroten i pridružena imena 50 mg kapsule s produljenim oslobađanjem, tvrde
The recommended daily dose is 25 mg - 75 mg. 
Preporučena početna doza je 25 mg - 75 mg.
The initial dose should be 10 mg - 25 mg in the evening. 
Početna doza treba biti 10 mg - 25 mg navečer.
QUALITATIVE AND QUANTITATIVE COMPOSITION [To be completed nationally] 
KVALITATIVNI I KVANTITATIVNI SASTAV
Recommended doses are 25 mg - 75 mg in the evening. 
Preporučene doze su 25 mg - 75 mg navečer.
If you use antidepressants such as SSRIs, your doctor might consider changing the dose of your medicine (see also section 2 Other medicines and X and section 3) 
Ako uzimate antidepresive kao što su selektivni inhibitori ponovne pohrane serotonina (SSRI), liječnik može razmotriti da Vam promijeni dozu lijeka (vidjeti također dio 2 Drugi lijekovi i X i dio 3).
What X contains <[Saroten and associated names prolonged-release capsules, hard ] The active substance is amitriptyline.> 
<[Saroten i pridružena imena kapsule s produljenim oslobađanjem, tvrde] Djelatna tvar je amitriptilin.
Not known Hypersensitivity myocarditis. 
rijetko aritmija vrlo rijetko kardiomiopatije, torsades de pointes nepoznato miokarditis povezan s preosjetljivošću
4.7 Effects on ability to drive and use machines 
4.7 Utjecaj na sposobnost upravljanja vozilima i rada sa strojevima Amitriptilin je sedativ.
Allergic inflammation of the pulmonary alveoli and of the lung tissue, respectively (alveolitis, Löffler's syndrome). 
Poremećaji dišnog sustava, prsišta i sredoprsja vrlo često začepljen nos vrlo rijetko alergijska upala plućnih alveola (alveolitis) i plućnog tkiva (Löfflerov sindrom)
• aggression 
• napadaje
<[Saroten and associated names prolonged-release capsules, hard ] Excipients 
<[Saroten i pridružena imena kapsule s produljenim oslobađanjem, tvrde]
[To be completed nationally] 10. 
[Ispunjava država članica].
Arrhythmia. 
Dojenje
• medicine to treat high blood pressure for example calcium-channel blockers (e.g. diltiazem and verapamil), guanethidine, betanidine, clonidine reserpine and methyldopa 
diltiazem i verapamil), gvanetidin, betanidin, klonidin, rezerpin i metildopa
Thioridazine: Co-administration of amitriptyline and thioridazine (CYP2D6 substrate) should be avoided due to inhibition of thioridazine metabolism and consequently increased risk of cardiac side effects 
Tioridazin: Potrebno je izbjegavati istovremenu primjenu amitriptilina i tioridazina (supstrat CYP2D6)
e.g.: 
u).
Very rare: may affect up to 1 in 10,000 people heart muscle disease feeling of inner restlessness and a compelling need to be in constant motion disorder of the peripheral nerves acute increase of pressure in the eye particular forms of abnormal heart rhythm (so called torsades de pointes) allergic inflammation of the lung alveoli and of the lung tissue 
- bolest srčanog mišića - osjećaj unutarnjeg nemira i nesavladive potrebe da se bude u stalnom pokretu - poremećaj perifernih živaca
Bed-wetting at night Use in children and adolescents The recommended doses for children: 
Preporučene doze za djecu:
The ECG characteristically show prolonged PR interval, widening of the QRS-complex, QT prolongation, T-wave flattening or inversion, ST segment depression, and varying degrees of heart block progressing to cardiac arrest. 
intervala, izravnanje ili inverziju T-vala, depresiju ST segmenta i razne stupnjeve srčanog bloka koji napreduje do srčanog aresta.
Heart rhythm disorders and hypotension may occur if you receive a high dosage of amitriptyline. 
Ako primate visoku dozu amitriptilina, mogu nastati poremećaji srčanog ritma i hipotenzija.
Your doctor will give you Saroten solution for injection. 
Saroten otopinu za injekciju davat će Vam liječnik.
• severe liver disease 
• shizofreniju • tešku bolest jetre
Uncommon Hypertension. 
hipokalemija.
Symptoms of overdose include: dilated pupils fast or irregular heartbeats difficulties passing water dry mouth and tongue intestinal blockage fits fever agitation confusion hallucinations uncontrolled movements low blood pressure, weak pulse, pallor difficulty breathing blue discolouration of the skin decreased heart rate drowsiness loss of consciousness coma various cardiac symptoms such as heart block, heart failure, hypotension, cardiogenic shock, metabolic acidosis, hypokalemia. 
Pretrage vrlo često povećanje tjelesne težine često abnormalni elektrokardiogram, produljeni QT interval na elektrokardiogramu, produljeni QRS kompleks na elektrokardiogramu, hiponatremija manje često povišen intraokularni tlak rijetko smanjena tjelesna težina, abnormalni rezultati testova jetrene funkcije, povišena alkalna fosfataza u krvi, povišene transaminaze.
NAME OF THE MARKETING AUTHORISATION HOLDER [See Annex I - To be completed nationally] EXPIRY DATE 
NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET [Vidjeti Prilog I.
• difficulty in passing urine 
• poteškoće s mokrenjem
Possible side effects 5. 
Moguće nuspojave 5. Kako čuvati X
Metabolism and nutrition disorders 
Poremećaji metabolizma i prehrane rijetko smanjeni apetit
Uncommon (> 1/1,000, < 1/100); 
Manje često (> 1/1000 i < 1/100);
• hair loss 
• oticanje žlijezda slinovnica • gubitak kose
Reproductive system and breast disorders 
MedDRA klasifikacija organskih sustava
• movement disorders (involuntary movements or decreased movements) 
• poremećaji pokreta (nevoljni pokreti ili smanjena pokretljivost) • upala srčanog mišića povezana s preosjetljivošću
Electrocardiogram abnormal, electrocardiogram QT prolonged, electrocardiogram QRS complex prolonged, hyponatremia. 
EKG karakteristično pokazuje produljeni PR interval, proširenje QRS kompleksa, produljenje QT
• Chronic tension type headache prophylaxis 
• profilaksa kronične tenzijske glavobolje
Ear and labyrinth disorders 
barbiturata i drugih depresora SŽS-a.
Recommended doses are 25 mg - 75 mg daily in the evening. 
Odrasli Preporučene doze su 25 mg - 75 mg na dan navečer.
Amitriptyline hydrochloride 
Djelatna tvar je amitriptilin hidroklorid.
Adults The recommended initial dose is 10 mg - 25 mg in the evening. 
Preporučena početna doza je 10 mg - 25 mg navečer.
Neuropathic pain, chronic tension type headache and migraine prophylaxis Your doctor will adjust the medication according to your symptoms and your response to the treatment. 
Liječnik će prilagoditi lijek sukladno Vašim simptomima i odgovoru na liječenje.
PHARMACEUTICAL FORM [To be completed nationally] 
POPIS POMOĆNIH TVARI [Ispunjava država članica]
• children aged 6 to 10 years: 10 mg - 20 mg. A suitable dosage form should be used for this age group. 
• djecu u dobi od 6 do 10 godina: 10 mg - 20 mg.
Rare: may affect up to 1 in 1,000 people decreased appetite delirium (especially in elderly patients), hallucinations (especially in patients with schizophrenia), abnormality in the heart's rhythm, or heartbeat pattern swelling of the salivary glands hair loss increased sensitivity to sunlight breast enlargement in men fever weight loss abnormal results of liver function tests 
Psihijatrijski poremećaji vrlo često agresija često stanje konfuzije, smanjeni libido, agitacija manje često hipomanija, manija, anksioznost, nesanica, noćna mora rijetko delirij (u starijih bolesnika), halucinacija (u bolesnika sa shizofrenijom), suicidalne misli ili ponašanje*
Gynaecomastia. 
receptorima.
• weight gain 
• povećanje tjelesne težine
Depending on your response to the medicine, your doctor may gradually increase the dose to a total daily dose of 100 mg divided in two doses. 
Ovisno o Vašem odgovoru na lijek, liječnik može postupno povećati dozu na ukupnu dnevnu dozu od
• thyroid medication. 
• lijekovi za štitnjaču.
• thyroid disease 
• bolest štitne žlijezde
excitement, anxiety, difficulties sleeping, nightmares convulsions tinnitus increased blood pressure diarrhoea, vomiting skin rash, nettle rash (urticarial), swelling of the face and tongue difficulties passing urine increased production of breast milk or breast milk outflow without breast feeding increased pressure in the eye ball collapse conditions worsening of cardiac failure liver function impairment (e.g. cholestatic liver disease) 
Poremećaji probavnog sustava vrlo često suha usta, zatvor, mučnina manje često proljev, povraćanje, edem jezika rijetko povećanje žlijezda slinovnica, paralitički ileus
Very common Orthostatic hypotension. 
Krvožilni poremećaji vrlo često ortostatska hipotenzija manje često hipertenzija nepoznato hipertermija
Amitriptyline hydrochloride> 
- Ispunjava država članica] amitriptilinklorid
It is important that you read this card carefully. 
Važno je pozorno pročitati karticu.
Tysabri was authorised in the European Union in June 2006. 
Tysabri je odobren u EU-u u lipnju 2006.
1 PRAC recommendations issued on 11 February 2016 
1 Preporuke PRAC-a objavljene 11. veljače 2016.
• If you have any questions or concerns, speak to your doctor, nurse or pharmacist. 
• Ako imate pitanja ili ste zabrinuti, obratite se svom liječniku, medicinskoj sestri ili ljekarniku.
Keep this card with you and make sure your partner or carer is aware of its content. 
Potrebno je sačuvati tu karticu i pobrinuti se da vaš partner ili njegovatelj bude upoznat s njezinim sadržajem.
The review of Tysabri was initiated on 7 May 2015 at the request of the European Commission, under Article 20 of Regulation (EC) No 726/2004. 
Pregled lijeka Tysabri pokrenut je 7. svibnja 2015. na zahtjev Europske komisije u skladu s člankom 20. Uredbe (EZ) br. 726/2004.
No index value 
Nema vrijednosti indeksa
Patients should be instructed to seek medical advice if they think their disease is getting worse, or if they notice any new or unusual symptoms. 
Bolesnike treba uputiti da zatraže medicinski savjet ako smatraju da se bolest pogoršava ili ako primijete nove ili neuobičajene simptome.
Index 0.9 or less 
Indeks od 0,9 ili manji
PML is a rare brain infection caused by John Cunningham (JC) virus. 
PML je rijetka infekcija mozga koju uzrokuje virus John Cunningham (JCV).
This protein is found on the surface of most leucocytes (the white cells in the blood that are involved in the inflammation process). 
Ova bjelančevina nalazi se na površini većine leukocita (bijelih krvnih stanica koje su uključene u proces upale).
Your doctor will also check for signs and symptoms suggestive of PML. 
Liječnik će također provjeravati znakove i simptome koji upućuju na PML.
The CHMP opinion was forwarded to the European Commission, which issued a final legally binding decision applicable in all EU Member States on 25/04/2016. 
Mišljenje CHMP-a proslijeđeno je Europskoj komisiji, koja je donijela konačnu pravno obvezujuću odluku primjenjivu u svim državama članicama EU-a dana 25/04/2016.
In light of the new evidence, patients are considered at higher risk of developing PML if they: 
U svjetlu novih dokaza, za bolesnike se smatra da imaju povećani rizik od razvoja PML-a ako su:
The CHMP's opinion was then sent to the European Commission, which issued a legally-binding decision valid throughout the EU. 
Mišljenje CHMP-a zatim je poslano Europskoj komisiji, koja je objavila pravno obvezujuću odluku koja vrijedi u cijelom EU-u.
EMA's recommendations are based on an initial review by its Pharmacovigilance Risk Assessment Committee (PRAC). 
EMA-ine preporuke temelje se na početnom pregledu Odbora za procjenu rizika u području farmakovigilancije (PRAC).
In these patients, treatment with Tysabri should only be continued if benefits outweigh the risks. 
U tih se bolesnika liječenje lijekom Tysabri treba nastaviti samo ako koristi nadmašuju rizike.
This virus is very common in the general population and is normally harmless; however, it can lead to PML in persons whose immune system is weakened. 
Virus je vrlo čest među općim stanovništvom i obično je bezopasan, međutim, u osoba s oslabljenim imunosnim sustavom može dovesti do PML-a.
The PRAC recommendations were sent to the Committee for Medicinal Products for Human Use (CHMP), which confirmed them and adopted its final opinion. 
Preporuke PRAC-a poslane su Odboru za lijekove za humanu uporabu (CHMP), koji ih je potvrdio i usvojio konačno mišljenje.
• have tested positive for JC virus, and 
• pozitivni na JCV i
The most common symptoms of PML are progressive weakness, speech and communication difficulties, vision changes, and sometimes changes in mood or behaviour. 
Najčešći simptomi PML-a su progresivna slabost, teškoće u govoru i komunikaciji, problemi s vidom te katkad promjene raspoloženja ili ponašanja.
It is used when the disease has failed to respond to treatment with a beta-interferon or glatiramer acetate (other types of medicines used in MS), or is severe and getting worse rapidly. 
Upotrebljava se u slučaju kada bolest na reagira na liječenje beta-interferonom ili glatirameracetatom (drugi lijekovi koji se upotrebljavaju u liječenju multiple skleroze) ili ako je bolest teška i brzo se pogoršava.
New recommendations have been issued which may help early detection of PML and improve patients' outcomes. 
Objavljene su nove preporuke koje mogu pomoći u ranom otkrivanju PML-a i u poboljšanju ishoda u bolesnika.
Considering these factors, your doctor will be able to advise you about your risk of developing PML. 
Uzevši u obzir ove čimbenike, liječnik može dati savjet o riziku od razvoja PML-a.
Tysabri is a medicine used to treat adults with highly active multiple sclerosis (MS), a disease of the nerves in which inflammation destroys the protective sheath surrounding the nerve cells. 
Tysabri je lijek koji se upotrebljava za liječenje odraslih osoba s visoko aktivnom multiplom sklerozom (MS), bolesti živaca u kojoj upala uništava zaštitni omotač živčanih stanica.
By attaching to the integrin, natalizumab stops the leucocytes from going from the blood into the brain, thereby reducing the inflammation and nerve damage caused by MS. 
Vezivanjem na integrin natalizumab sprječava prelazak leukocita iz krvi u mozak te time smanjuje upalu i oštećenje živaca uzrokovano multiplom sklerozom.
• Symptoms of PML may be similar to those of a multiple sclerosis attack, and include progressive weakness, speech and communication difficulties, vision problems, and sometimes changes in mood or behaviour. 
• Simptomi PML-a mogu biti slični simptomima multiple skleroze, a uključuju progresivnu slabost, teškoće u govoru i komunikaciji, probleme s vidom te katkad promjene raspoloženja ili ponašanja.
• PML should be considered in the differential diagnosis of any patient presenting with neurological symptoms and/or new brain lesions on MRI. 
• PML je potrebno razmotriti pri diferencijalnoj dijagnozi svakog bolesnika s neurološkim simptomima i/ili novim lezijama na mozgu na MR-u.
2 PML risk estimates were derived using the life table method based on the pooled cohort of 21,696 patients who participated in the STRATIFY-2, TOP, TYGRIS, and STRATA clinical studies. 
2 Procjene rizika od PML-a izvedene su metodom tablice duljine života udružene skupine od 21 696 bolesnika koji su sudjelovali u kliničkim ispitivanjima STRATIFY-2, TOP, TYGRIS, i STRATA.
The PRAC recommendations were then sent to the Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which adopted the Agency's final opinion. 
Preporuke PRAC-a zatim su poslane Odboru za lijekove za humanu uporabu (CHMP), odgovornom za pitanja koja se odnose na lijekove za humanu uporabu, koji je usvojio konačno mišljenje Agencije.
• have been treated with Tysabri for more than 2 years, and 
• ako su liječeni lijekom Tysabri dulje od dvije godine te
Patients who have low index values and no history of prior immunosuppressant use should also be retested every 6 months once they reach the 2-year treatment point. 
Bolesnici s niskim vrijednostima indeksa i koji nisu prethodno uzimali imunosupresive također se trebaju ponovno testirati svakih šest mjeseci nakon što prođu dvije godine od početka liječenja.
Recent studies suggest that early detection and treatment of PML when the disease is asymptomatic (is still in the initial stages and shows no symptoms) may improve patients' outcomes. 
Nedavna ispitivanja upućuju na to da rano otkrivanje i liječenje PML-a kada je bolest asimptomatska (još u početnim fazama i nema vidljivih simptoma) može poboljšati ishode u bolesnika.
All patients taking Tysabri should undergo full MRI scans at least once a year, but on the basis of the new data EMA recommended that for patients at higher risk of PML more frequent MRI scans (e.g. every 3 to 6 months) performed using simplified protocols should be considered. 
Svi bolesnici koji uzimanju Tysabri trebali bi najmanje jedanput godišnje otići na snimanje MR-om, a EMA je na temelju novih podataka preporučila da je u bolesnika s povećanim rizikom od PML-a potrebno razmotriti češće snimanje MR-om (npr. svakih 3 do 6 mjeseci) primjenom pojednostavljenih protokola.
More detailed information on the risk stratification, diagnosis and treatment of PML will be included in the updated Physician Information and Management Guidelines for Tysabri. 
Detaljnije informacije o stratifikaciji rizika, dijagnozi i liječenju PML-a bit će uvrštene u ažurirane Informacije za liječnike i smjernice za liječenje lijekom Tysabri.
EMA confirms recommendations to minimise risk of brain infection PML with Tysabri 
EMA potvrđuje preporuke za minimizaciju rizika od PML-a povezanog s lijekom Tysabri
Index 0.9 to 
Indeks od 0,9 do 1,5
No prior use of immunosuppressants 
Bez prethodne uporabe imunosupresiva
In patients who tested negative for JC virus antibodies, the PML risk estimate remains unchanged at 0.1 per 1,000 patients. 
U bolesnika s negativnim testom na JCV protutijela procjena rizika od PML-a ostaje nepromijenjena, odnosno 0,1 na 1 000 bolesnika.
Prior use of immunosuppressants 
Uz prethodnu uporabu imunosupresiva
Asymptomatic cases of PML can be detected on MRI scans, and experts in the field of MRI and multiple sclerosis agree that simplified MRI protocols (which allow for shorter procedures, and also limit the burden for patients undergoing the scans) permit the identification of PML lesions. 
Asimptomatski slučajevi PML-a mogu se otkriti magnetskom rezonancijom (MR), a stručnjaci u području MR-a i multiple skleroze slažu se da pojednostavljeni protokoli za MR (u kojima je postupak snimanja kraći, čime se dodatno smanjuje opterećenje za bolesnike koji idu na snimanje) omogućuju otkrivanje lezija u PML-u.
On 25 February 2016, EMA completed its review of the known risk of progressive multifocal leukoencephalopathy (PML) with the multiple sclerosis medicine Tysabri (natalizumab), and confirmed initial recommendations1 aimed at minimising this risk. 
EMA je dovršila pregled poznatog rizika od progresivne multifokalne leukoencefalopatije (PML) povezane s lijekom Tysabri (natalizumab) za liječenje multiple skleroze te je potvrdila početne preporuke1 u cilju minimizacije tog rizika.
• Progressive multifocal leukoencephalopathy (PML, a serious brain infection) is known to be an uncommon risk with the multiple sclerosis medicine Tysabri. 
• Progresivna multifokalna leukoencefalopatija (PML, ozbiljna infekcija mozga) rijedak je rizik povezan s primjenom lijeka Tysabri za liječenje multiple skleroze.
• During treatment with Tysabri, patients should be monitored at regular intervals for signs and symptoms of new neurological dysfunction, and a full brain MRI should be performed at least once a year for the duration of treatment. 
• Bolesnike je tijekom liječenja lijekom Tysabri potrebno pratiti u redovitim razmacima kako bi se uočili znakovi i simptomi nove neurološke disfunkcije te je potrebno napraviti snimanje MR-om cijelog mozga najmanje jedanput godišnje tijekom trajanja liječenja.
• either have used an immunosuppressant before starting Tysabri, or have not used immunosuppressants and have a high JC virus antibody index. 
• prije uporabe lijeka Tysabri upotrebljavali imunosupresive ili nisu upotrebljavali imunosupresive, a imaju visok indeks JCV protutijela.
The active substance in Tysabri, natalizumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a specific part of a protein called ‘α4β1 integrin'. 
Djelatna tvar lijeka Tysabri jest natalizumab, monoklonsko protutijelo (vrsta bjelančevina) koje prepoznaje i veže se na specifični dio bjelančevine koja se naziva α4ß1 integrin.